Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks
-
Reich, Kristian (Dermatologikum Berlin)
;
Warren, R. B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ;
Iversen, Lars (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Pau-Charles, I. (Almirall R&D) ;
Igarashi, A. (NTT Medical Center Tokyo) ;
Ohtsuki, M. (Jichi Medical University) ;
Falqués, M. (Almirall R&D) ;
Harmut, M. (Almirall R&D) ;
Rozzo, S. (Sun Pharmaceuticals) ;
Lebwohl, M. G. (Icahn School of Medicine at Mount Sinai) ;
Cantrell, W. (University of Alabama at Birmingham) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Thaçi, Diamant (University of Lübeck) ;
Universitat Autònoma de Barcelona
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
